Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methyprylon SCHEMBL614 | 0.68 | LMNA (0.40) | LMNATSHRALDH1A1NPSR1 | |
| Methyprylon SCHEMBL155839 | 0.68 | LMNA (0.40) | LMNATSHRALDH1A1NPSR1 | |
| Methyprylon SCHEMBL155838 | 0.68 | LMNA (0.40) | LMNATSHRALDH1A1NPSR1 | |
| SCHEMBL31509083 | 0.66 | LMNA (0.78) | LMNATSHRALDH1A1KDM4ECYP3A4 | |
| SCHEMBL28588519 | 0.64 | LMNA (0.65) | LMNATSHRALDH1A1KDM4ECYP3A4 | |
| SCHEMBL14788875 | 0.64 | LMNA (0.64) | LMNATSHRALDH1A1KDM4ENPSR1 | |
| Barbital SCHEMBL3859278 | 0.62 | LMNA (1.00) | LMNATSHRALDH1A1KDM4ECYP3A4 | |
| Barbital SCHEMBL43818 | 0.62 | LMNA (1.00) | LMNATSHRALDH1A1KDM4ECYP3A4 | |
| SCHEMBL13881643 | 0.62 | LMNA (0.37) | LMNATSHRALDH1A1HTTKDM4E | |
| Barbital SCHEMBL236590 | 0.60 | LMNA (0.94) | LMNATSHRALDH1A1KDM4ECYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420694-B2 | Pyrrolidin-2-one derivatives as androgen receptor modulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-04-16 | — | — | US | disclosed |
| US-8420694-B2 | Pyrrolidin-2-one derivatives as androgen receptor modulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-04-16 | — | — | US | disclosed |
| US-8420694-B2 | Pyrrolidin-2-one derivatives as androgen receptor modulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-04-16 | — | — | US | disclosed |
| EP-2176220-B1 | Pyrrolidin-2-one derivatives as androgen receptor modulators | TAKEDA PHARMACEUTICAL (JP) | 2013-03-27 | — | — | EP | disclosed |
| EP-2176220-B1 | Pyrrolidin-2-one derivatives as androgen receptor modulators | TAKEDA PHARMACEUTICAL (JP) | 2013-03-27 | — | — | EP | disclosed |
| US-20110098336-A1 | PYRROLIDIN-2-ONE DERIVATIVES AS ANDROGEN RECEPTOR MODULATOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-04-28 | — | — | US | disclosed |
| US-20110098336-A1 | PYRROLIDIN-2-ONE DERIVATIVES AS ANDROGEN RECEPTOR MODULATOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-04-28 | — | — | US | disclosed |
| US-20110098336-A1 | PYRROLIDIN-2-ONE DERIVATIVES AS ANDROGEN RECEPTOR MODULATOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-04-28 | — | — | US | disclosed |
| US-7834051-B2 | Cyclic amine compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-16 | — | — | US | disclosed |
| US-7834051-B2 | Cyclic amine compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-16 | — | — | US | disclosed |
| US-7834051-B2 | Cyclic amine compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-16 | — | — | US | disclosed |
| EP-2176220-A2 | PYRROLIDIN-2-ONE DERIVATIVES AS ANDROGEN RECEPTOR MODULATOR | Takeda Pharmaceutical Company Limited (JP) | 2010-04-21 | — | — | EP | disclosed |
| WO-2009020234-A2 | PYRROLIDIN-2 -ONE DERIVATIVES AS ANDROGEN RECEPTOR MODULATOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-02-12 | — | — | WO | disclosed |
| WO-2009020234-A2 | PYRROLIDIN-2 -ONE DERIVATIVES AS ANDROGEN RECEPTOR MODULATOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-02-12 | — | — | WO | disclosed |
| US-20090042967-A1 | Cyclic amine compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-02-12 | — | — | US | disclosed |
| US-20090042967-A1 | Cyclic amine compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-02-12 | — | — | US | disclosed |
| US-20090042967-A1 | Cyclic amine compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098336-A1 | PYRROLIDIN-2-ONE DERIVATIVES AS ANDROGEN RECEPTOR MODULATOR | AR, NR5A1, SHBG | LMNA 4654/4885TSHR 437/4885ALDH1A1 788/4885 |
| US-20090042967-A1 | Cyclic amine compounds | SHBG, FSHR, ACP3 | LMNA 1213/4885TSHR 1132/4885ALDH1A1 1734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.